A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

It’s been heady for biotechs break­ing in­to a pan­dem­ic stock mar­ket: $233 mil­lion for ADC Ther­a­peu­tics, $165 mil­lion for Zen­tal­is, and $120 mil­lion for ORIC. Now a com­pa­ny that emerged from stealth just 8 months ago — and is now run­ning low on cash — is try­ing to get in on the 9-fig­ure game.

South San Fran­cis­co-based Ap­plied Mol­e­c­u­lar Trans­port has filed for a $100 mil­lion IPO. Found­ed and led by long­time life sci­ences con­sul­tant Tahir Mah­mood, the com­pa­ny builds oral drugs around a car­ri­er mol­e­cule that can cross pro­tec­tive lin­ings in­to the im­mune-cell heavy ar­eas of the gut. They de­buted in Sep­tem­ber, af­ter they be­gan dos­ing Phase I for their lead pro­gram, an ul­cer­a­tive col­i­tis drug that re­cent­ly com­plet­ed ear­ly test­ing in East­ern Eu­rope.

Tahir Mah­mood

That drug, AMT-101, is an IL-10 ag­o­nist that is de­signed to turn down in­flam­ma­tion in au­toim­mune dis­or­ders, in­clud­ing ul­cer­a­tive col­i­tis but al­so pou­ch­i­tis and rheuma­toid arthri­tis. The IPO, the com­pa­ny said, will bankroll both Phase II tri­als for AMT-101 that they plan to be­gin this year, and a Phase I tri­al for AMT-126, an IL-22 ag­o­nist be­ing de­vel­oped for dis­eases that are re­lat­ed to bar­ri­er func­tion — i.e. dis­eases that sci­en­tists be­lieve in­volve breach­es in the cell lin­ing of the gut, such as in­flam­ma­to­ry bow­el dis­ease.

The swift IPO arose at least part­ly out of a sober look at their fi­nan­cials, with man­age­ment con­clud­ing at the end of Q1 that there “was sub­stan­tial doubt about our abil­i­ty to con­tin­ue as a go­ing con­cern” for the fol­low­ing year.

Ap­plied Mol­e­c­u­lar Trans­port was ini­tial­ly found­ed in 2010, as Ap­plied Mol­e­c­u­lar Trans­port, LLC. But in 2016, Ap­plied Mol­e­c­u­lar Trans­port, LLC be­came a whol­ly owned sub­sidiary of a new en­ti­ty — Ap­plied Mol­e­c­u­lar Trans­port Inc. Since then, the com­pa­ny has qui­et­ly raised $105.6 mil­lion in three sep­a­rate rounds: A $32.8 mil­lion Se­ries A in 2016, a $30.9 mil­lion Se­ries B in 2018, and a $41.9 mil­lion Se­ries C in 2019.

The com­pa­ny, though, burned through over $15 mil­lion in Q1 — $10 mil­lion more than they burned through in Q1 2019, when they were still a pre­clin­i­cal com­pa­ny — and was left with just $16 mil­lion left in the tank.

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Geoffrey Porges, new Schrödinger CFO

Long­time an­a­lyst Ge­of­frey Porges de­parts SVB to lead fi­nances at a drug dis­cov­ery shop

Geoffrey Porges has ended his two-decade run as a biotech analyst, as the former SVB Securities vice chair began as CFO of Schrödinger on Thursday.

The long-running analyst, who previously headed up vaccines marketing at Merck before the turn of the millennium, will lead the financial operations of the 700-employee company as Schrödinger broadens its focus from a drug discovery partner to also building out an in-house pipeline, with clinical trial No. 1 set to begin next quarter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

The FDA on Wednesday approved the first gene therapy for a chronic condition — bluebird bio’s new Zynteglo (beti-cel) as a potentially curative treatment for those with transfusion-dependent thalassemia.

The thumbs-up from the FDA follows a unanimous adcomm vote in June, with outside experts pointing to extraordinary efficacy, with 89% of subjects with TDT who received beti-cel having achieved transfusion independence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Joel Dudley, new partner at Innovation Endeavors (Bosch Health Campus)

For­mer Google CEO’s VC is mak­ing a big­ger push in­to the biotech world, hir­ing promi­nent Ther­a­nos skep­tic

Venture capital firm Innovation Endeavors has mainly had its focus on investments across the tech space, but it has been slowly turning its attention to the biotech world. Now, a new partner is coming into the fold showing that its interest in biotech is likely to grow further.

The Silicon Valley-based company, which is headed up by former Google CEO Eric Schmidt, has brought on Joel Dudley as a partner. According to Dudley’s LinkedIn page, he is joining Innovation Endeavors after serving as the chief science officer of biotech startup Tempus Labs since 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

James Sabry, Roche global head of pharma partnering

Roche, Genen­tech plunk down $60M up­front to part­ner with Chi­nese phar­ma on PRO­TAC-based prostate can­cer drug

Roche and Genentech are always on the hunt for deals, and on Thursday they found their newest partner.

The pair will team up with the Chinese pharma company Jemincare to push forward a new program for prostate cancer, the companies announced. Roche is ponying up $60 million upfront to get its hands on the candidate and promising up to $590 million in biobucks, plus royalties, down the line.

In return, Genentech will get a worldwide license to develop the program, known as JMKX002992, and bring it to market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Andrew Hopkins, Exscientia CEO

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

Bayer and Exscientia are winding down their three-year collaboration, leaving the big German pharma to take the AI-designed compounds born out of the pact further.

London-based Exscientia revealed in its Q2 update that the partners have “mutually agreed to end” their collaboration, which kicked off in early 2020, after recently achieving a drug discovery milestone. In an SEC filing, Exscientia said it terminated the pact on May 30, about six months early.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,400+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”